Inhibiting multiple molecular pathways with biologic therapies is an attractive treatment strategy for cancer [ 3] and currently under investigation for R/M-SCCHN [ 4].
In a recent retrospective cohort study, Tamariz and colleagues evaluated patient persistence with teriparatide and other osteoporosis medications as compared to persistence with biologic therapies used to treat rheumatoid arthritis (RA) and multiple sclerosis (MS) [ 12].
Combination specific PAH therapy in CTD-PAH targets more than one of the multiple biologic pathways involved in disease pathogenesis [ 2].
At present, novel and expensive biologic therapies are being developed to address this unmet need.
For patients whose uveitis condition is refractory to traditional immunosuppressants, biologic therapies may be considered.
Note: For new biologic therapies approved since the "Delphi panel", average scores were applied depending on class.
Figure 4 presents the relationship between baseline SIFRA scores and the use of biologic therapies in the follow-up period.
Such cLBP is often termed nonspecific and may be due to multiple biologic and behavioral etiologies.
Even for those with moderate-to-severe psoriasis, biologic therapies are expensive [3], are not equally effective in all patients [4], and the long-term safety profile (>5 years) of immunosuppressive biologics is not fully established [5].
